ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Analyst Coverage
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Press Releases

Investors & Media

  • Home
  • Investors & Media
  • News / Events
  • Press Releases
Investors & Media

Investors & Media

  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • Events
    • Email Alerts
  • Presentations
  • Company Information
  • Financial Information
  • Analyst Coverage
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

ContraFect to Present at 28th Annual Piper Jaffray Healthcare Conference

November 23, 2016

ContraFect Awarded $2.1 Million PRMRP Grant to Support Development of CF-301

November 17, 2016

ContraFect Announces Expanded Research Collaboration with The Rockefeller University to Identify Lysin Therapeutics Targeting Gram-negative Bacteria

November 14, 2016

ContraFect to Present at The Lysin Meeting

November 10, 2016

ContraFect Reports Third Quarter 2016 Financial Results and Provides Business Update

November 9, 2016

ContraFect Announces Organizational Changes

September 16, 2016

ContraFect Announces Second Quarter 2016 Results

August 9, 2016

ContraFect Receives Designation as a Small and Medium Enterprise by the European Medicines Agency

August 4, 2016

ContraFect Corporation Prices $35 Million Public Offering of Common Stock and Warrants

July 22, 2016

ContraFect Corporation Names Steven C. Gilman, PhD Chief Executive Officer

July 21, 2016

RSS
  • 1
  • 2
  • 3
  • Next »
© 2023 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter